Cargando…

Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyhoun, Iman, Hajighasemlou, Saieh, Ai, Jafar, Hosseinzadeh, Faezeh, Mirmoghtadaei, Milad, Seyhoun, Seyed Moein, Parseh, Benyamin, Abdolahi, Shahrokh, Ghazvinian, Zeinab, Shadnoush, Mahdi, Verdi, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/
https://www.ncbi.nlm.nih.gov/pubmed/30678447
http://dx.doi.org/10.31557/APJCP.2019.20.1.263
_version_ 1783414276113825792
author Seyhoun, Iman
Hajighasemlou, Saieh
Ai, Jafar
Hosseinzadeh, Faezeh
Mirmoghtadaei, Milad
Seyhoun, Seyed Moein
Parseh, Benyamin
Abdolahi, Shahrokh
Ghazvinian, Zeinab
Shadnoush, Mahdi
Verdi, Javad
author_facet Seyhoun, Iman
Hajighasemlou, Saieh
Ai, Jafar
Hosseinzadeh, Faezeh
Mirmoghtadaei, Milad
Seyhoun, Seyed Moein
Parseh, Benyamin
Abdolahi, Shahrokh
Ghazvinian, Zeinab
Shadnoush, Mahdi
Verdi, Javad
author_sort Seyhoun, Iman
collection PubMed
description OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. METHODS: HepG2 cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare the inhibition of cell growth between the two groups with different treatments. RESULTS: The combination treatment of cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib alone (3.4 vs. 2.7 respectively). CONCLUSION: This study suggests that a combination of sorafenib with MSC-CM can synergistically suppress the growth of HCC cells.
format Online
Article
Text
id pubmed-6485565
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-64855652019-05-13 Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells Seyhoun, Iman Hajighasemlou, Saieh Ai, Jafar Hosseinzadeh, Faezeh Mirmoghtadaei, Milad Seyhoun, Seyed Moein Parseh, Benyamin Abdolahi, Shahrokh Ghazvinian, Zeinab Shadnoush, Mahdi Verdi, Javad Asian Pac J Cancer Prev Research Article OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that a lower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumor growth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture and contains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effect of sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. METHODS: HepG2 cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and compare the inhibition of cell growth between the two groups with different treatments. RESULTS: The combination treatment of cell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenib alone (3.4 vs. 2.7 respectively). CONCLUSION: This study suggests that a combination of sorafenib with MSC-CM can synergistically suppress the growth of HCC cells. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6485565/ /pubmed/30678447 http://dx.doi.org/10.31557/APJCP.2019.20.1.263 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Seyhoun, Iman
Hajighasemlou, Saieh
Ai, Jafar
Hosseinzadeh, Faezeh
Mirmoghtadaei, Milad
Seyhoun, Seyed Moein
Parseh, Benyamin
Abdolahi, Shahrokh
Ghazvinian, Zeinab
Shadnoush, Mahdi
Verdi, Javad
Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title_full Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title_fullStr Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title_full_unstemmed Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title_short Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
title_sort novel combination of mesenchymal stem cell-conditioned medium with sorafenib have synergistic antitumor effect of hepatocellular carcinoma cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/
https://www.ncbi.nlm.nih.gov/pubmed/30678447
http://dx.doi.org/10.31557/APJCP.2019.20.1.263
work_keys_str_mv AT seyhouniman novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT hajighasemlousaieh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT aijafar novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT hosseinzadehfaezeh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT mirmoghtadaeimilad novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT seyhounseyedmoein novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT parsehbenyamin novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT abdolahishahrokh novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT ghazvinianzeinab novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT shadnoushmahdi novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells
AT verdijavad novelcombinationofmesenchymalstemcellconditionedmediumwithsorafenibhavesynergisticantitumoreffectofhepatocellularcarcinomacells